Assembly Biosciences vs Compugen
Assembly Biosciences and Compugen are similar in size: $72.3m and $72.8m of revenue in their latest fiscal years. Compugen grew faster (161.1% against 153.5%). Compugen kept more of each dollar of sales as profit: a net margin of 48.6% against -8.5%. Assembly Biosciences carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Assembly BiosciencesASMB, 2025 | CompugenCGEN, 2025 |
|---|---|---|
| Revenue | $72.3m | $72.8m |
| Revenue growth | 153.5% | 161.1% |
| Net income | −$6.1m | $35.3m |
| Operating margin | -16.8% | 43.1% |
| Net margin | -8.5% | 48.6% |
| Return on equity | -5.1% | 44.8% |
| Free cash flow | −$41.2m | $31.3m |
| Cash | $58.5m | $90.6m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $392m | $191m |
| Price vs our value range | — | Below our value range |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 12 sales |